Wall Street Zen lowered shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) from a hold rating to a sell rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.
Other equities research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a report on Wednesday, November 4th. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. HC Wainwright dropped their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, BTIG Research restated a “buy” rating and issued a $57.00 price target on shares of vTv Therapeutics in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, vTv Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.83.
View Our Latest Research Report on vTv Therapeutics
vTv Therapeutics Price Performance
vTv Therapeutics stock opened at $19.69 on Friday. vTv Therapeutics has a fifty-two week low of $19.04 and a fifty-two week high of $44.00. The firm has a market capitalization of $78.96 million, a price-to-earnings ratio of -21.40 and a beta of 0.29. The company’s 50 day simple moving average is $28.04 and its 200 day simple moving average is $32.91.
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.15. As a group, analysts predict that vTv Therapeutics will post -2.58 EPS for the current fiscal year.
Hedge Funds Weigh In On vTv Therapeutics
A hedge fund recently raised its position in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. lifted its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT – Free Report) by 114.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,360 shares of the biotechnology company’s stock after purchasing an additional 2,860 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.51% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics is a U.S. clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for serious diseases. Its research has focused on metabolic conditions and other areas of significant medical need. The company’s candidates have included cadisegliatin, formerly known as TTP399, an oral glucokinase activator studied as an addition to insulin therapy for people with type 1 diabetes, and azeliragon, an investigational compound studied for Alzheimer’s disease. These are development-stage products, not established commercial medicines.
Further Reading
- Five stocks we like better than vTv Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
